James Chun-Yen Kuo
UNSW Sydney · 29 works · 4,470 citations · h-index 12
Top works
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
- Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients
- Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
- Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review
- Regorafenib-induced hyperammonemic encephalopathy
- Administration of chemotherapy in patients on dialysis
- OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC
- Treatment outcomes of rapid desensitisation protocols for chemotherapeutic agents and monoclonal antibodies following hypersensitivity reactions
- Application of hypersensitivity skin testing in chemotherapy-induced pneumonitis
- Renal Failure Requiring Hemodialysis in Two Patients with Metastatic Breast Cancer Treated with Everolimus
- How well informed is the informed consent for cancer clinical trials?
- CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
- Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)
- A Rapid Access Clinic to improve delivery of ambulatory care to cancer patients
- Immune Checkpoint Inhibitors in the Treatment of Advanced Mucosal Melanoma
- Serious hepatic complications of selective internal radiation therapy with yttrium‐90 microsphere radioembolization for unresectable liver tumors
- A Randomized Trial of the Electronic Lung Cancer Symptom Scale for Quality-of-Life Assessment in Patients with Advanced Non-small-Cell Lung Cancer
- Combined Cancer Patient–Reported Symptom and Health Utility Tool for Routine Clinical Implementation: A Real-World Comparison of the ESAS and EQ-5D in Multiple Cancer Sites
- OA01.06 Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRASG12C Inhibitor, in Patients with Non-Small Cell Lung Cancer